4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
• 英文别名: cis-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester；ethyl 4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylate
• 化学式: C₂₄H₂₃ClF₆N₂O₄
• 分子量: 552.901
• InChiKey: YYACOOAIDRMDBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester 、 F₃ CSO₃ NO₂ 生成 cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-8-nitro-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1114033A1

  公开（公告）日：2001-07-11
• PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
  申请人：Bend Research, Inc.

  公开号：EP2258352B1

  公开（公告）日：2015-05-13
• US6147090A
  申请人：——

  公开号：US6147090A

  公开（公告）日：2000-11-14
• US6395751B1
  申请人：——

  公开号：US6395751B1

  公开（公告）日：2002-05-28
• [EN] 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS<br/>[FR] 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDRO-QUINOLEINE UTILISEES COMME INHIBITEURS DE LA PROTEINE DE TRANSFERT D'ESTER DE CHOLESTERYLE (CETP)
  申请人：PFIZER PROD INC

  公开号：WO2000017166A1

  公开（公告）日：2000-03-30

  Cholesteryl ester transfer protein inhibitors of formula (I), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.